1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-114703S
    Eslicarbazepine-d3
    Eslicarbazepine-d3 (BIA 2-194-d3) is the deuterium labeled Eslicarbazepine (HY-114703). Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.
    Eslicarbazepine-d<sub>3</sub>
  • HY-162609
    ST-2560
    Inhibitor
    ST-2560 is a selective inhibitor of the NaV1.7 sodium channel with IC50 value of 39 nM. ST-2560 can be used to study pain behavior and cardiovascular models.
    ST-2560
  • HY-127004
    Silperisone hydrochloride
    Inhibitor
    Silperisone hydrochloride is an organosilicone compound similar to tolperisone that has centrally acting muscle relaxant properties. Silperisone (hydrochloride) is a sodium channel protein type 2 alpha channel blocker that blocks sodium and calcium channels in cells, reduces muscle cell excitability and contraction, reduces peripheral tone, and acts as a muscle relaxant and peripheral vascular dilator. Silperisone (hydrochloride) is used to study recurrent painful myoclonus due to spinal cord injury, abnormal hypertonia due to cerebrovascular disease, myotonia symptoms, pyramidal tonia syndrome, multiple sclerosis myospasm, and myelitis.
    Silperisone hydrochloride
  • HY-B0516AR
    Articaine (Standard)
    Inhibitor
    Articaine (Standard) is the analytical standard of Articaine (HY-B0516A). This product is intended for research and analytical applications. Articaine (Hoe-045) hydrochloride is a selective inhibitor of voltage-gated sodium channels (such as rNav1.4, hNav1.7, and rNav1.8), with an IC50 of 15.8 μM for open-state Na+ channels, and IC50 of 40.6 μM and 378 μM for inactivated and resting-state Na+ channels, respectively. Articaine hydrochloride exerts local anesthetic activity by inhibiting Na+ influx to block nerve impulse conduction, and can also inhibit NF-κB activation and NLRP3 inflammasome pathways, exhibiting anti-inflammatory function. Articaine hydrochloride can be used in the study of dental local anesthesia and inflammatory-related diseases (such as acute kidney injury).
    Articaine (Standard)
  • HY-B0495S3
    Lamotrigine-13C2,15N
    Lamotrigine-13C2,15N is the 13C and 15N labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al.
    Lamotrigine-<sup>13</sup>C<sub>2</sub>,<sup>15</sup>N
  • HY-P5865
    Tap1a
    Inhibitor
    Tap1a (Theraphotoxin-Tap1a) is a spider venom peptide that inhibits sodium channels with IC50s of 80 nM and 301 nM against Nav1.7 and Nav1.1, respectively. Tap1a shows analgesic effects.
    Tap1a
  • HY-122001
    PF-05186462
    Inhibitor 99.69%
    PF-05186462 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channel, with an IC50 of 21 nM. PF-05186462 shows significant selectivity for Nav1.7 versus other sodium channels (Nav 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, and 1.8). PF-05186462 can be used for the research of acute or chronic pain.
    PF-05186462
  • HY-161272
    Nav1.8-IN-6
    Inhibitor
    Nav1.8-IN-6 (Compound 2j) is a novel pyridinone amide Nav1.8 channel inhibitor. The IC50 values in the resting state and semi-activated state are 513.33 and 471.81 nM, respectively. Nav1.8-IN-6 has analgesic activity.
    Nav1.8-IN-6
  • HY-P5790
    μ-TRTX-Hd1a
    Inhibitor
    μ-TRTX-Hd1a, a spider venom, is a selective NaV 1.7 inhibitor. μ-TRTX-Hd1a is a gating modifier that inhibits human NaV 1.7 by interacting with the S3b-S4 paddle motif in channel domain II.
    μ-TRTX-Hd1a
  • HY-16259
    Indecainide hydrochloride
    Inhibitor
    Indecainide hydrochloride is a potent and orally active class I local anesthetic antiarrhythmic agent. Indecainide hydrochloride has Na+-channel-blocking activity.
    Indecainide hydrochloride
  • HY-B0517S
    Mepivacaine-d3
    Inhibitor 99.0%
    Mepivacaine-d3 is the deuterium labeled Mepivacaine. Mepivacaine is an amide-type local anesthetic agent. Mepivacaine binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization.
    Mepivacaine-d<sub>3</sub>
  • HY-B0280S
    Ranolazine-d5
    Inhibitor
    Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP). Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor. Antianginal agent.
    Ranolazine-d<sub>5</sub>
  • HY-160588
    Nav1.8-IN-7
    Inhibitor
    Nav1.8-IN-7 (Example 116) is a selective Nav1.8 inhibitor. Nav1.8-IN-7 shows an inhibition of >50% with 100 nM for Nav1.8. Nav1.8-IN-7 inhibits hERG with an IC50 of 15.6 μM. Nav1.8-IN-7 has the potential for pain research.
    Nav1.8-IN-7
  • HY-155017
    6-Iodoamiloride
    Inhibitor
    6-Iodoamiloride is a potent acid-sensing ion channel 1 (ASIC1) inhibitor with an IC50 of 88 nM. 6-Iodoamiloride inhibits ASIC3-mediated currents from rat dorsal root ganglion neurons with an IC50 of 230 nM.
    6-Iodoamiloride
  • HY-A0081R
    Fluphenazine dihydrochloride (Standard)
    Inhibitor
    Fluphenazine (dihydrochloride) (Standard) is the analytical standard of Fluphenazine (dihydrochloride). This product is intended for research and analytical applications. Fluphenazine dihydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dihydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine dihydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dihydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dihydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
    Fluphenazine dihydrochloride (Standard)
  • HY-P5781
    δ-Theraphotoxin-Hm1b
    Inhibitor
    δ-Theraphotoxin-Hm1b is a 42-amino acid peptide isolated from Togo starburst tarantula (Heteroscodra maculata) venom. δ-Theraphotoxin-Hm1b selectively inhibits inactivation of NaV1.1 but have no effect on NaV1.7.
    δ-Theraphotoxin-Hm1b
  • HY-116119
    BDF 9148
    Activator
    BDF 9148 is a sodium-channel activator with antiarrhythmic properties that produces a significant CAMP-independent positive inotropic effect in left ventricular myocardium from failing hearts. BDF 9148 is promising for research of myocardial failure.
    BDF 9148
  • HY-117494
    Flumethiazide
    Flumethiazide (NSC 44626) is an orally active diuretic agent. Flumethiazide has marked diuretic and natruretic effects with significant effects on Sodium, Chloride and water but not on potassium excretion. Flumethiazide can be used for cardiac diseases like essential hypertension research.
    Flumethiazide
  • HY-149305
    PptT-IN-4
    Inhibitor
    PptT-IN-4 (Compound 3a) is a PptT inhibitor (IC50: 0.71 μM). PptT-IN-4 inhibits Mtb H37Rv with a MIC value of 42 μM. PptT-IN-4 also inhibits hERG, hCav1.2, and hNav1.5 channels with IC50s of 11 μM, 8.1 μM, 6.9 μM respectively.
    PptT-IN-4
  • HY-P5809
    Pe1b
    Inhibitor
    Pe1b (μ-TrTx-Pe1b) is a selective Nav1.7 inhibitor with an IC50 of 167 nM.
    Pe1b
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.